Business Context and Reporting Period
This Form 8-K is a current report filed by TherapeuticsMD, Inc. (Nasdaq: TXMD), a Nevada corporation, on January 15, 2026. The filing primarily addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the administrative change of auditors.
Material Changes
- Change in Certifying Accountant: The Audit Committee approved the appointment of Carr, Riggs & Ingram, L.L.C. (CRI) as the new independent registered public accounting firm, effective immediately on January 15, 2026.
- Reason for Change: The prior auditor, Berkowitz Pollack Brant Advisors + CPAs (BPB), ceased serving as a result of a transaction where CRI acquired certain assets related to BPB's capital markets practice.
- Audit History: BPB's audit reports for fiscal years ended December 31, 2024, and December 31, 2023, did not contain adverse opinions or disclaimers. However, they included an explanatory paragraph regarding the uncertainty of the Company's ability to continue as a going concern.
- Disagreements: The Company reported no "disagreements" or "reportable events" with BPB during the fiscal years ended December 31, 2025, and 2024, or through the date of dismissal.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the previously noted going concern uncertainty. The transition of the audit firm is described as a result of an asset acquisition between the two firms rather than a dispute over accounting principles.
Investor Verification Checklist
- Verify the status of the "going concern" uncertainty noted in the 2023 and 2024 audit reports to assess current liquidity risks.
- Review the attached letter from BPB (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the change.
- Monitor upcoming filings (e.g., 10-K or 10-Q) for the first financial statements audited by CRI to ensure continuity in reporting standards.
- Confirm that no undisclosed disagreements or reportable events exist between the Company and the new auditor, CRI.